Ruagen

Regor Therapeutics, officially registered as Ruagen (Shanghai) Biotechnology Co., Ltd., is a clinical-stage biotechnology company focused on discovering and developing innovative small molecule medicines. The company utilizes its proprietary CARD (Computer Accelerated Rational Discovery) platform, which integrates structural biology, computational chemistry, and biology to streamline the drug discovery process. Regor's primary therapeutic focus includes metabolic diseases, oncology, and autoimmune disorders. The company is well-known for its significant strategic collaboration with Eli Lilly, established in 2021, to develop novel therapies for metabolic disorders. Its lead clinical candidates include RGT-075, an oral GLP-1 receptor agonist for type 2 diabetes and obesity, and RGT-419B, a selective CDK4/6 inhibitor for the treatment of breast cancer.